ArticleHealth economics review2025
Economic burden of end stage renal disease: a case study in southern Iran.
Article in Health economics review, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Supportive care needs and associated factors in hemodialysis patients: a cross-sectional study.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe condition of renal failure is widely regarded as one of the most significant challenges currently facing public health and typically treated through hemodialysis. The objective of this study was to estimate the Economic burden of hemodialysis in Bushehr province and, by extension, Iran.
methodThis was a cross-sectional and partial economic evaluation study conducted to estimate the Economic burden of hemodialysis using the bottom-up approach in Bushehr province and, consequently Iran. Direct medical costs and the number of hemodialysis patients were attained from health information system (HIS). Indirect costs were calculated by including the cost of lost production due to hospitalization, rest at home, absenteeism from work, and also the loss of productivity due to premature death. finally, to reduce the uncertainty around the data, a two-way sensitivity analysis was carried out.
resultThe mean cost of hemodialysis per patient was calculated to be 169,016 $ Purchasing Power Parity (PPP) resulting in a total economic burden of hemodialysis for Bushehr province and Iran in 2022 as 13,849,321 and 977,677,441$ (which is equivalent to 0.3% Iran's GDP) PPP respectively in 2022. The highest proportion of overall costs (52%) was attributable to indirect costs. Premature death accounted for 82.1% of this figure. While, the largest cost component within the direct costs category (57.2%) belonged to the professional and technical tariffs.
conclusionHemodialysis imposes a significant economic burden on Iranian society. In 2022, the annual cost of hemodialysis for Iran was approximately equivalent to 0.3% of the country's GDP. Preventive measures targeting the factors that predispose individuals to hemodialysis need to be seriously considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.